Articles

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA
Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon, France
European Institute of Oncology, Milan, Italy
University of Nebraska Medical Center, Omaha, NE, USA
Hospital Universitario de Salamanca, Spain
Hospital Duran i Reynals-ICO, Barcelona, Spain
Ondokuz Mayis University, Samsun, Turkey
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Novartis Healthcare Pvt. Ltd., Hyderabad, India
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Vol. 102 No. 12 (2017): December, 2017 https://doi.org/10.3324/haematol.2017.169656